How Much Does Saxenda Cost in Connecticut in 2026?

Saxenda Retail Pricing in Connecticut

The manufacturer list price set by Novo Nordisk for Saxenda is $1,349 per month, representing a 30-day supply of five 3 mL prefilled pens. Connecticut retail pharmacies, including CVS, Walgreens, and independent locations, charge at or near this list price for cash-pay patients without insurance or discount programs.

This price has remained stable through early 2026. Saxenda entered the market in 2014 at approximately $1,000 per month and has seen incremental increases since then. Unlike semaglutide products that have experienced supply disruptions, liraglutide supply has remained consistent in Connecticut throughout 2025 and into 2026.

Price variation between pharmacies in Connecticut is minimal for brand-name Saxenda because Novo Nordisk controls the wholesale acquisition cost. Patients paying full retail should expect $1,349 regardless of whether they fill at a chain pharmacy in Hartford, a Costco in Stamford, or an independent in New Haven. The one variable: some pharmacies charge a dispensing fee on top of acquisition cost, adding $5 to $15.

The SCALE Obesity and Prediabetes trial (N=3,731) demonstrated that liraglutide 3 mg produced 8.0% mean body weight loss at 56 weeks compared to 2.6% with placebo 1. For patients weighing 220 lbs at baseline, that translates to roughly 17.6 lbs of weight reduction. The clinical benefit must be weighed against cumulative annual costs exceeding $16,000 at full retail.

Connecticut Medicaid Coverage for Saxenda

Connecticut Medicaid does cover Saxenda, but requires prior authorization before dispensing. This is standard across most state Medicaid programs for GLP-1 receptor agonists prescribed for weight management.

To obtain PA approval through Connecticut's HUSKY Health program, prescribers typically must document: a BMI of 30 or greater (or 27 or greater with at least one weight-related comorbidity such as type 2 diabetes, hypertension, or dyslipidemia), failure of lifestyle modification over a defined period (usually 3 to 6 months), and confirmation that the patient does not have a history of medullary thyroid carcinoma or MEN2 syndrome.

The PA process in Connecticut usually takes 24 to 72 hours for standard requests. Urgent requests can be processed same-day. If denied, patients have the right to appeal through the Department of Social Services fair hearing process.

According to the FDA-approved prescribing information, liraglutide 3 mg is contraindicated in patients with a personal or family history of medullary thyroid carcinoma and in patients with Multiple Endocrine Neoplasia syndrome type 2 [2]. Connecticut Medicaid formulary reviewers screen for these contraindications during the PA process.

One important detail: Connecticut Medicaid does not require patients to fail metformin or orlistat before approving Saxenda, unlike some neighboring states. This removes one barrier to access for Medicaid beneficiaries in the state.

Commercial Insurance Coverage in Connecticut

Coverage for Saxenda across Connecticut's commercial insurance market is inconsistent. The major carriers operating in Connecticut (Anthem, Aetna, Cigna, UnitedHealthcare, and ConnectiCare) each maintain separate formulary decisions for anti-obesity medications.

Anthem Blue Cross Blue Shield plans in Connecticut generally cover Saxenda on Tier 3 or specialty tier with PA requirements similar to Medicaid: documented BMI threshold, lifestyle modification attempt, and absence of contraindications. Copays on Tier 3 typically range from $75 to $150 per month before the savings card is applied.

Cigna plans sold through Access Health CT (Connecticut's state exchange) have varied year to year. Some 2026 silver and gold plans include anti-obesity medications with PA; bronze plans frequently exclude them. Patients should verify coverage by calling the number on their insurance card and asking specifically about "liraglutide 3 mg for chronic weight management" rather than using the brand name alone, as pharmacy benefit systems sometimes route differently by generic name.

UnitedHealthcare employer-sponsored plans in Connecticut often require step therapy, meaning patients must document a trial of a lower-cost option (typically orlistat or phentermine-topiramate) before Saxenda is approved. Self-funded employer plans may have different criteria entirely, as the employer controls the formulary.

Dr. Caroline Apovian, a past president of The Obesity Society, has stated: "Insurance barriers to anti-obesity medications remain the single greatest obstacle to evidence-based obesity treatment in the United States. Prior authorization requirements delay care and disproportionately burden patients who already face health disparities." This observation applies directly to the Connecticut market, where PA requirements add administrative delays even when coverage technically exists.

The Novo Nordisk Savings Card

Novo Nordisk offers a manufacturer savings card for Saxenda that can reduce out-of-pocket costs to $25 per month for commercially insured patients. The card is available to patients with private or commercial insurance and is not valid for those on Medicare, Medicaid, TRICARE, or other government-funded programs.

Eligibility requirements are straightforward. The patient must have commercial insurance that covers Saxenda (even partially), must be a resident of the United States or Puerto Rico, and must not be enrolled in any federal or state healthcare program. Connecticut residents with employer-sponsored or individual market commercial plans typically qualify.

The savings card covers up to $200 off each 30-day prescription fill, with a maximum annual benefit that Novo Nordisk adjusts periodically. In practice, patients with insurance copays between $25 and $225 per month can bring their cost down to $25 using this card.

How to activate: patients register at the Novo Nordisk patient assistance website or receive a card through their prescriber's office. The card functions as a secondary payer at the pharmacy counter. Present it alongside the primary insurance card at pickup.

One limitation: if the primary insurer denies coverage entirely (not just requiring a copay, but rejecting the claim), the savings card does not apply. It is a copay assistance program, not a coverage replacement.

Compounded Liraglutide 3 mg in Connecticut

Compounded liraglutide 3 mg is available in Connecticut through licensed 503A compounding pharmacies. These pharmacies operate under state board of pharmacy oversight and federal guidance from the Drug Quality and Security Act of 2013.

A 503A pharmacy compounds medications pursuant to individual patient prescriptions. In Connecticut, this means a physician, nurse practitioner, or physician assistant must write a patient-specific prescription for compounded liraglutide, and the pharmacy prepares the formulation for that individual patient.

Pricing for compounded liraglutide varies significantly between pharmacies. Some Connecticut-based and out-of-state 503A pharmacies shipping into Connecticut have offered compounded liraglutide at prices ranging from $200 to $500 per month, well below the $1,349 brand-name price. The exact cost depends on the pharmacy's sourcing of bulk liraglutide API (active pharmaceutical ingredient), their compounding overhead, and markup.

Patients should verify several factors before using a compounded product: confirm the pharmacy holds a valid Connecticut pharmacy license or is properly registered for out-of-state shipping into Connecticut, ask about beyond-use dating (compounded injectables typically have shorter shelf lives than manufactured products), and confirm sterility testing protocols. The Connecticut Department of Consumer Protection, Drug Control Division, oversees pharmacy licensing in the state.

The FDA has noted that compounded drugs are not FDA-approved and do not undergo the same manufacturing oversight as commercially manufactured products 2. Patients choosing compounded liraglutide should discuss this distinction with their prescriber.

Telehealth Prescribing of Saxenda in Connecticut

Connecticut permits telehealth prescribing of Saxenda. The state's telehealth laws, expanded during 2020 and made permanent through subsequent legislation, allow licensed prescribers to evaluate patients via audio-video consultation and prescribe controlled and non-controlled medications including GLP-1 receptor agonists for weight management.

Saxenda is not a controlled substance, which simplifies the telehealth prescribing pathway. A Connecticut-licensed physician, APRN, or PA can conduct an initial weight management evaluation entirely via telehealth, order relevant labs (metabolic panel, A1c, lipid panel, thyroid function), review results electronically, and prescribe liraglutide 3 mg without an in-person visit.

Several national telehealth platforms serve Connecticut patients for obesity medicine consultations. HealthRX offers telehealth-based weight management evaluations with clinicians who can prescribe Saxenda and manage the prior authorization process with the patient's insurance.

The American Association of Clinical Endocrinology (AACE) 2016 guidelines recommend pharmacotherapy for patients with BMI ≥30, or BMI ≥27 with complications, when lifestyle intervention alone is insufficient 3. These same criteria apply whether the visit is conducted in person or via telehealth in Connecticut.

Discount Programs and Cost-Reduction Strategies

Beyond the Novo Nordisk savings card, Connecticut patients have several options to reduce Saxenda costs.

GoodRx and similar discount cards. These aggregators negotiate cash prices with pharmacies. For Saxenda specifically, discounts are modest because the wholesale acquisition cost is high and margins are thin. Typical GoodRx prices in Connecticut pharmacies range from $1,200 to $1,349, saving $0 to $150 off list price. Not substantial, but worth checking.

Novo Nordisk Patient Assistance Program (PAP). Uninsured patients or those with household income below 400% of the federal poverty level may qualify for free Saxenda through the manufacturer's PAP. For 2026 to 400% FPL for a single individual is approximately $62,400. Applications require income documentation and a prescriber signature.

Specialty pharmacy mail order. Some PBMs (pharmacy benefit managers) require Saxenda to be filled through a specialty or mail-order pharmacy. While this does not always reduce the copay, it can simplify refills and sometimes offers 90-day supply pricing that effectively reduces per-month cost by 5 to 10%.

Employer wellness program subsidies. A growing number of Connecticut employers, particularly in the insurance and financial sectors concentrated in Hartford, offer supplemental benefits for weight management medications. Patients should ask their HR department whether anti-obesity medications are covered under wellness or disease management programs separate from the standard pharmacy benefit.

The SCALE Maintenance trial demonstrated that patients who continued liraglutide 3 mg after initial weight loss maintained significantly more weight reduction than those switched to placebo, losing an additional 6.2% of body weight versus a 0.2% regain in the placebo group over 56 weeks 4. This durability data supports long-term use, making cost sustainability a practical concern for Connecticut patients.

How Saxenda Compares to Other GLP-1 Options in Connecticut

Saxenda is not the only GLP-1 receptor agonist available for weight management in Connecticut. Patients and prescribers should consider the full cost picture.

Wegovy (semaglutide 2.4 mg weekly) carries a list price of approximately $1,349 per month, similar to Saxenda, but offers once-weekly dosing versus daily. The STEP-1 trial (N=1,961) showed semaglutide 2.4 mg produced 14.9% mean weight loss at 68 weeks versus 2.4% with placebo 5, roughly double the efficacy of liraglutide 3 mg.

Zepbound (tirzepatide) for weight management has a similar price point with potentially greater efficacy based on the SURMOUNT trials. However, availability has been more variable than Saxenda through 2025 and early 2026.

For patients whose primary barrier is cost rather than efficacy preference, the choice between Saxenda and Wegovy may depend on which product their specific Connecticut insurer covers with lower cost-sharing. Some plans cover Wegovy but not Saxenda, or vice versa. The Endocrine Society's 2024 guidelines note that selection among GLP-1 receptor agonists should consider patient preference, insurance coverage, and tolerability alongside efficacy data 6.

Dr. Robert Kushner, professor of medicine at Northwestern University, has observed: "The best weight management medication is the one the patient can access, afford, and tolerate over the long term. A medication with 15% mean weight loss means nothing if the patient cannot fill the prescription month after month."

Starting Saxenda: Dose Titration and What to Expect

Saxenda requires a 4-week dose escalation to reach the maintenance dose of 3 mg daily. The schedule: 0.6 mg daily for week 1 to 1.2 mg for week 2 to 1.8 mg for week 3 to 2.4 mg for week 4, then 3 mg daily from week 5 onward.

This titration affects early costs. During the first month, patients use less medication per day than at maintenance dosing, meaning the first carton of pens lasts longer than 30 days. Depending on pharmacy policies, this can delay the second fill and effectively extend the first month's supply to 6 weeks.

Common side effects during titration include nausea (reported in 39% of patients in SCALE trials), diarrhea, constipation, and injection site reactions 1. Most gastrointestinal side effects diminish after 4 to 8 weeks. Patients who cannot tolerate the 3 mg dose may remain at 2.4 mg, though the FDA label specifies discontinuation if 3 mg is not tolerated, as efficacy was established at the full dose.

Connecticut prescribers should evaluate response at 16 weeks. Per the FDA label, if a patient has not lost at least 4% of baseline body weight by week 16 on the 3 mg dose, Saxenda should be discontinued as meaningful further response is unlikely 2. This 16-week checkpoint also represents a natural cost evaluation point: $4,047 to $5 to 396 in medication cost by that time at full retail, less with insurance or savings card.